BCL2L1 and breast carcinoma: Inhibition of BCL-2/BCL-XL has shown anti-cancer function in preclinical models of breast cancer where navitoclax inhibits TNBC patient derived xenograft (PDX) growth when administered in combination with docetaxel [100].